1. Home
  2. MURA vs NVNI Comparison

MURA vs NVNI Comparison

Compare MURA & NVNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • NVNI
  • Stock Information
  • Founded
  • MURA 2013
  • NVNI 2019
  • Country
  • MURA Ireland
  • NVNI Brazil
  • Employees
  • MURA N/A
  • NVNI N/A
  • Industry
  • MURA
  • NVNI
  • Sector
  • MURA
  • NVNI
  • Exchange
  • MURA Nasdaq
  • NVNI Nasdaq
  • Market Cap
  • MURA 45.8M
  • NVNI 39.5M
  • IPO Year
  • MURA N/A
  • NVNI N/A
  • Fundamental
  • Price
  • MURA $2.62
  • NVNI $0.35
  • Analyst Decision
  • MURA Strong Buy
  • NVNI
  • Analyst Count
  • MURA 4
  • NVNI 0
  • Target Price
  • MURA $13.00
  • NVNI N/A
  • AVG Volume (30 Days)
  • MURA 206.7K
  • NVNI 24.3M
  • Earning Date
  • MURA 05-14-2025
  • NVNI 06-10-2025
  • Dividend Yield
  • MURA N/A
  • NVNI N/A
  • EPS Growth
  • MURA N/A
  • NVNI N/A
  • EPS
  • MURA N/A
  • NVNI N/A
  • Revenue
  • MURA N/A
  • NVNI $31,250,627.00
  • Revenue This Year
  • MURA $34.35
  • NVNI $25.91
  • Revenue Next Year
  • MURA N/A
  • NVNI $21.68
  • P/E Ratio
  • MURA N/A
  • NVNI N/A
  • Revenue Growth
  • MURA N/A
  • NVNI 1491.58
  • 52 Week Low
  • MURA $0.95
  • NVNI $0.14
  • 52 Week High
  • MURA $4.74
  • NVNI $12.19
  • Technical
  • Relative Strength Index (RSI)
  • MURA 50.82
  • NVNI 44.87
  • Support Level
  • MURA $2.59
  • NVNI $0.37
  • Resistance Level
  • MURA $2.72
  • NVNI $0.44
  • Average True Range (ATR)
  • MURA 0.15
  • NVNI 0.05
  • MACD
  • MURA -0.02
  • NVNI -0.00
  • Stochastic Oscillator
  • MURA 29.41
  • NVNI 4.46

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

Share on Social Networks: